Civil Rights
Block on Trump's Asylum Ban Upheld by Supreme Court
A national registry of Accutane users began accepting names on December 30, 2005. The iPLEDGE program, intended to keep track of persons currently using the anti-acne drug, requires health care providers and pharmacists to identify all patients who have been prescribed and/or sold Accutane, or any generic version of the drug (isotretinoin). The goal of the registry is to reduce the incidence of pregnancy-related harm caused by the drug, including birth defects and birth injuries.
Sign into your Legal Forms and Services account to manage your estate planning documents.
Sign InCreate an account allows to take advantage of these benefits: